Author

Priyanka D. Sehgal

Children's Hospital of PhiladelphiaORCID 0000-0003-2231-4564Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:biophysical modeling· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Andrei Thomas‐TikhonenkoiD· 3 shared Katharina E. HayeriD· 3 shared Adam Cain ResnickiD· 2 shared Ammar S. NaqviiD· 2 shared Annette CastroiD· 2 shared Jamie B. SpangleriD· 2 shared Jo Lynne RokitaiD· 2 shared Justyn Fine· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Andrei Thomas‐TikhonenkoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJan 26, 2026

The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target

Zhiwei Ang, Annette Castro, Luca Paruzzo…·Andrei Thomas‐Tikhonenko

The paper identifies P2RX5 as a new B-cell surface marker and multi-lineage immunotherapy target, showing its expression in B-cell malignancies and T-cell leukemia, and demonstrating the efficacy of P2RX5-directed therapies.

DOI 10.64898/2026.01.14.698748

humanbulk RNA-seq

𝕏 PostBluesky

GenomicsNeuro-Oncology PediatricsPeer-reviewedJan 1, 2026

Alternative splicing in pediatric central nervous system tumors highlights oncofetal candidate CLK1 exon 4

Ammar S. Naqvi, Patricia J. Sullivan, Ryan J. Corbett…·Jo Lynne Rokita

The paper analyzes splicing in 729 pediatric brain tumors, identifies splicing-defined subgroups, and highlights CLK1 exon 4 as an oncofetal event linked to tumor prognosis.

7 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyCell ReportsPeer-reviewedAug 1, 2025

NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas

Priyanka D. Sehgal, Ammar S. Naqvi, Makenna Higgins…·Andrei Thomas‐Tikhonenko

The paper identifies a NRCAM proteoform with skipped microexons as a targetable surface antigen in pHGG and demonstrates its utility in immunotherapy.

6 citations

humanbulk RNA-seq

𝕏 PostBluesky